TrialDiabetes, obesity & metabolism2025

Assessing the effects of naltrexone-bupropion on hepatic steatosis and fibrosis in patients with T2DM and overweight or obesity: Insights from a placebo-controlled trial.

Alina N Saidi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.